PT-141 – 10mg

PT-141 (Bremelanotide) is a synthetic melanocortin peptide and direct metabolite of Melanotan II. Produced through removal of the C terminal amide group from the MT-2 structure, that achieved FDA approval under the brand name Vyleesi for hypoactive sexual desire disorder, contributing a well documented human clinical literature base that distinguishes it from most research peptide compounds. iLab Pharma’s 10mg lyophilized vial delivers a higher concentration standalone presentation than CSD’s Hudson Science 10mg nasal spray at equivalent total compound with the lyophilized injectable vial format serving distinct research purposes from the intranasal delivery system.

The 10mg lyophilized vial and 10mg nasal spray serve complementary research purposes within CSD’s PT-141 range. The nasal spray format’s intranasal delivery provides proximity to the olfactory epithelium and potential direct CNS access via the olfactory nerve pathway. A pharmacokinetically relevant advantage for PT-141’s primary MC3R and MC4R hypothalamic targets where central nervous system receptor engagement is the principal research variable. The lyophilized vial’s reconstitute format supports subcutaneous parenteral administration research. The administration route most extensively documented in PT-141’s clinical trial literature including the Vyleesi approval studies alongside in vitro melanocortin receptor binding studies and comparative bioavailability research between intranasal and parenteral delivery at matched concentration.

PT-141’s most pharmacologically significant research characteristic is its PDE5 independent mechanism of action, producing central nervous system mediated arousal response through hypothalamic MC4R activation and downstream dopaminergic pathway modulation rather than the peripheral vascular smooth muscle relaxation mechanism of PDE5 inhibitors like sildenafil. This CNS mediated mechanism makes PT-141 a distinctly different research tool from vascular targeted sexual health compounds. Operating at the hypothalamic level where desire and arousal initiation occurs rather than at the peripheral vascular level where physical response is facilitated. The MC3R and MC4R selectivity that produces this CNS focused profile also explains PT-141’s significantly reduced MC1R melanogenic activity compared to Melanotan II; making it the preferred melanocortin research compound for sexual health and CNS arousal pathway studies where pigmentation endpoint confounding is an unwanted research variable.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks PT-141 across two formats: this iLab Pharma 10mg lyophilized vial and the Hudson Science 10mg nasal spray, alongside Melanotan II across vial and nasal spray formats, giving researchers complete melanocortin receptor agonist delivery route and comparative compound flexibility from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside Melanotan II in comparative melanocortin receptor selectivity and central nervous system signaling studies. Browse CSD’s full peptide range for complete sourcing.